239 related articles for article (PubMed ID: 17596871)
1. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
Chen Y; Lin MC; Yao H; Wang H; Zhang AQ; Yu J; Hui CK; Lau GK; He ML; Sung J; Kung HF
Hepatology; 2007 Jul; 46(1):200-8. PubMed ID: 17596871
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
3. Proteomic analysis of EZH2 downstream target proteins in hepatocellular carcinoma.
Chen Y; Lin MC; Wang H; Chan CY; Jiang L; Ngai SM; Yu J; He ML; Shaw PC; Yew DT; Sung JJ; Kung HF
Proteomics; 2007 Sep; 7(17):3097-104. PubMed ID: 17676662
[TBL] [Abstract][Full Text] [Related]
4. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
5. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
6. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo.
Chen Y; Xie D; Yin Li W; Man Cheung C; Yao H; Chan CY; Chan CY; Xu FP; Liu YH; Sung JJ; Kung HF
Cancer Lett; 2010 Nov; 297(1):109-16. PubMed ID: 20684863
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans.
Yang F; Zhang L; Huo XS; Yuan JH; Xu D; Yuan SX; Zhu N; Zhou WP; Yang GS; Wang YZ; Shang JL; Gao CF; Zhang FR; Wang F; Sun SH
Hepatology; 2011 Nov; 54(5):1679-89. PubMed ID: 21769904
[TBL] [Abstract][Full Text] [Related]
8. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
9. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
10. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
[TBL] [Abstract][Full Text] [Related]
11. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.
Bie CQ; Liu XY; Cao MR; Huang QY; Tang HJ; Wang M; Cao GL; Yi TZ; Wu SL; Xu WJ; Tang SH
Oncotarget; 2016 Nov; 7(48):79305-79318. PubMed ID: 27813495
[TBL] [Abstract][Full Text] [Related]
12. RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy.
Tang B; Zhang Y; Liang R; Gao Z; Sun D; Wang L
Oncol Rep; 2013 Mar; 29(3):1037-42. PubMed ID: 23291714
[TBL] [Abstract][Full Text] [Related]
13. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells.
Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F
Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083
[TBL] [Abstract][Full Text] [Related]
14. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
15. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
[TBL] [Abstract][Full Text] [Related]
16. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2.
Liu F; He Y; Shu R; Wang S
Int J Clin Exp Pathol; 2015; 8(5):4972-80. PubMed ID: 26191190
[TBL] [Abstract][Full Text] [Related]
18. 20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
Li Q; Li B; Dong C; Wang Y; Li Q
Eur J Pharmacol; 2017 Nov; 815():173-180. PubMed ID: 28928088
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma.
Huang Y; Tao Y; Hu K; Lin F; Li X; Feng T; Wang ZM
Tumour Biol; 2016 Nov; 37(11):14903-14914. PubMed ID: 27644248
[TBL] [Abstract][Full Text] [Related]
20. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.
Chiba T; Suzuki E; Negishi M; Saraya A; Miyagi S; Konuma T; Tanaka S; Tada M; Kanai F; Imazeki F; Iwama A; Yokosuka O
Int J Cancer; 2012 Jun; 130(11):2557-67. PubMed ID: 21717453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
